Promising preclinical activity of 2-Methoxyestradiol in multiple myeloma

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: 2-Methoxyestradiol (2ME2), a natural endogenous product of estradiol metabolism, has demonstrated activity against tumor cell lines and can inhibit angiogenesis. There are limited treatment options for patients with multiple myeloma (MM) who relapse after high-dose therapy and stem cell transplantation. We studied the preclinical activity of 2ME2 as a therapeutic agent for myeloma. Experimental Design: Five established myeloma cell lines as well as primary plasma cells from patients with MM were exposed to 2ME2 at various concentrations. We evaluated the activity of the drug to inhibit cell replication and induction of apoptosis in vitro as well as the ability of the drug to inhibit myeloma tumor xenograft growth in severe combined immunodeficient mice. Results: 2ME2 inhibited tritiated thymidine uptake in all myeloma cell lines tested in a dose-dependent fashion and induced G2-M phase cell cycle arrest. The drug induced apoptosis in all cell lines tested and in half of the primary plasma cells evaluated in a dose-response manner. Forty-eight h after drug exposure, a large proportion of the cells were dead by propidium iodide staining. Injection of the drug i.p. suppressed myeloma tumor xenograft growth, and the effect was sustained after cessation of therapy. Conclusions: 2ME2 has significant activity against myeloma cell lines and primary myeloma cells both in vitro and in an animal model. Clinical trials are required to evaluate its activity in patients with MM.

Original languageEnglish (US)
Pages (from-to)3948-3954
Number of pages7
JournalClinical Cancer Research
Volume8
Issue number12
StatePublished - Dec 1 2002

Fingerprint

Multiple Myeloma
Cell Line
Pharmaceutical Preparations
Plasma Cells
Heterografts
Apoptosis
M Phase Cell Cycle Checkpoints
SCID Mice
Propidium
G2 Phase
Stem Cell Transplantation
Therapeutics
Growth
Tumor Cell Line
Thymidine
Estradiol
Neoplasms
Research Design
Animal Models
2-methoxyestradiol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Promising preclinical activity of 2-Methoxyestradiol in multiple myeloma. / Dingli, David M; Timm, Michael; Russell, Stephen J; Witzig, Thomas Elmer; Rajkumar, S Vincent.

In: Clinical Cancer Research, Vol. 8, No. 12, 01.12.2002, p. 3948-3954.

Research output: Contribution to journalArticle

@article{04b0a1877f024c9ab3386ffbe9b0f440,
title = "Promising preclinical activity of 2-Methoxyestradiol in multiple myeloma",
abstract = "Purpose: 2-Methoxyestradiol (2ME2), a natural endogenous product of estradiol metabolism, has demonstrated activity against tumor cell lines and can inhibit angiogenesis. There are limited treatment options for patients with multiple myeloma (MM) who relapse after high-dose therapy and stem cell transplantation. We studied the preclinical activity of 2ME2 as a therapeutic agent for myeloma. Experimental Design: Five established myeloma cell lines as well as primary plasma cells from patients with MM were exposed to 2ME2 at various concentrations. We evaluated the activity of the drug to inhibit cell replication and induction of apoptosis in vitro as well as the ability of the drug to inhibit myeloma tumor xenograft growth in severe combined immunodeficient mice. Results: 2ME2 inhibited tritiated thymidine uptake in all myeloma cell lines tested in a dose-dependent fashion and induced G2-M phase cell cycle arrest. The drug induced apoptosis in all cell lines tested and in half of the primary plasma cells evaluated in a dose-response manner. Forty-eight h after drug exposure, a large proportion of the cells were dead by propidium iodide staining. Injection of the drug i.p. suppressed myeloma tumor xenograft growth, and the effect was sustained after cessation of therapy. Conclusions: 2ME2 has significant activity against myeloma cell lines and primary myeloma cells both in vitro and in an animal model. Clinical trials are required to evaluate its activity in patients with MM.",
author = "Dingli, {David M} and Michael Timm and Russell, {Stephen J} and Witzig, {Thomas Elmer} and Rajkumar, {S Vincent}",
year = "2002",
month = "12",
day = "1",
language = "English (US)",
volume = "8",
pages = "3948--3954",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Promising preclinical activity of 2-Methoxyestradiol in multiple myeloma

AU - Dingli, David M

AU - Timm, Michael

AU - Russell, Stephen J

AU - Witzig, Thomas Elmer

AU - Rajkumar, S Vincent

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Purpose: 2-Methoxyestradiol (2ME2), a natural endogenous product of estradiol metabolism, has demonstrated activity against tumor cell lines and can inhibit angiogenesis. There are limited treatment options for patients with multiple myeloma (MM) who relapse after high-dose therapy and stem cell transplantation. We studied the preclinical activity of 2ME2 as a therapeutic agent for myeloma. Experimental Design: Five established myeloma cell lines as well as primary plasma cells from patients with MM were exposed to 2ME2 at various concentrations. We evaluated the activity of the drug to inhibit cell replication and induction of apoptosis in vitro as well as the ability of the drug to inhibit myeloma tumor xenograft growth in severe combined immunodeficient mice. Results: 2ME2 inhibited tritiated thymidine uptake in all myeloma cell lines tested in a dose-dependent fashion and induced G2-M phase cell cycle arrest. The drug induced apoptosis in all cell lines tested and in half of the primary plasma cells evaluated in a dose-response manner. Forty-eight h after drug exposure, a large proportion of the cells were dead by propidium iodide staining. Injection of the drug i.p. suppressed myeloma tumor xenograft growth, and the effect was sustained after cessation of therapy. Conclusions: 2ME2 has significant activity against myeloma cell lines and primary myeloma cells both in vitro and in an animal model. Clinical trials are required to evaluate its activity in patients with MM.

AB - Purpose: 2-Methoxyestradiol (2ME2), a natural endogenous product of estradiol metabolism, has demonstrated activity against tumor cell lines and can inhibit angiogenesis. There are limited treatment options for patients with multiple myeloma (MM) who relapse after high-dose therapy and stem cell transplantation. We studied the preclinical activity of 2ME2 as a therapeutic agent for myeloma. Experimental Design: Five established myeloma cell lines as well as primary plasma cells from patients with MM were exposed to 2ME2 at various concentrations. We evaluated the activity of the drug to inhibit cell replication and induction of apoptosis in vitro as well as the ability of the drug to inhibit myeloma tumor xenograft growth in severe combined immunodeficient mice. Results: 2ME2 inhibited tritiated thymidine uptake in all myeloma cell lines tested in a dose-dependent fashion and induced G2-M phase cell cycle arrest. The drug induced apoptosis in all cell lines tested and in half of the primary plasma cells evaluated in a dose-response manner. Forty-eight h after drug exposure, a large proportion of the cells were dead by propidium iodide staining. Injection of the drug i.p. suppressed myeloma tumor xenograft growth, and the effect was sustained after cessation of therapy. Conclusions: 2ME2 has significant activity against myeloma cell lines and primary myeloma cells both in vitro and in an animal model. Clinical trials are required to evaluate its activity in patients with MM.

UR - http://www.scopus.com/inward/record.url?scp=0036897507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036897507&partnerID=8YFLogxK

M3 - Article

C2 - 12473611

AN - SCOPUS:0036897507

VL - 8

SP - 3948

EP - 3954

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -